Peregrine Pharmaceuticals is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the diagnosis and treatment of cancer. The company is pursuing a number of clinical programs in cancer with its lead product candidate, Bavituximab, and also its novel brain cancer agent, Cotara.
The company announced today results from its 70-patient, open-label, randomized Phase II clinical trial of bavituximab used in conjunction with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer. The trial included patients with advanced metastatic disease including significant liver involvement and poor health associated with rapid disease progression.
Results of the trial showed that the combination of the two drugs resulted in more than a doubling of overall response rates and an improvement in overall survival when compared with the use of gemcitabine alone in the control group. Patients treated with the combination had a 28% tumor response rate versus a 13% response rate in the control group.
Needless to say, Peregrine is pleased with the results of the trial. Further analysis of the data shows some subgroups with some interesting and potentially promising trends. The company is considering potential development pathways that would allow it to take advantage of bavituximab's broader possibilities with other cancer agents.
For additional information about Peregrine Pharmaceutical, please visit www.peregrine.com
Sign up for "The Mission Report" at www.MissionIR.com